Bayer HealthCare has announced the 2014 recipients of the Bayer Hemophilia Awards Program (BHAP), which is dedicated to supporting innovative research and educational initiatives to benefit individuals with hemophilia worldwide. This year, the company awarded more than $2 million in funding to 14 recipients in five countries. Five American researchers and clinicians received awards, representing the largest group of awardees from one country.
BHAP research funding is focused on advancing treatment and discovering methods to alleviate disease burden. The 2014 projects include cutting-edge approaches for product replacement therapy and genomic editing to correct specific gene mutations.
2014 BHAP winners from the US are:
- Brian Brown, Icahn School of Medicine at Mount Sinai, New York
- Lacramioara Ivanciu, The Children’s Hospital of Philadelphia
- Juan Melero-Martin, Boston Children’s Hospital, Harvard Medical School
- Jordan Shavit, University of Michigan, Ann Arbor
- Suman Sood, University of Michigan, Ann Arbor
Since 2002, BHAP has awarded more than 230 grants totaling more than $28 million in funding. Grants have been awarded to researchers and caregivers from 30 countries, contributing to more than 400 publications, poster presentations and other scientific communications by awardees.
“BHAP, now in its twelfth year, continues to attract high-quality applicants who are committed to answering important scientific and medical questions. Through our support of their research, this year’s winners will contribute to a better understanding of hemophilia and bleeding disorders and ways to improve treatment and optimize patient outcomes,” said Prasad Mathew, MD, Vice President, Global Medical Affairs Hematology, Bayer HealthCare.
Source: PRNewswire, May 16, 2014
